3′-Deoxy-3′-[18f]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3791-3798

  Barthel, Henryk ^a,c   Cleij, Marcel C ^a   Collingridge, David R ^a   Hutchinson, O Clyde ^a   Osman, Safiye ^b   He, Qimin ^d   Luthra, Sajinder K ^b   Brady, Frank ^b   Price, Pat M ^a   Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; 3' FLUOROTHYMIDINE; ADENOSINE TRIPHOSPHATE; CYCLINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; THYMIDINE KINASE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STABILITY; DRUG UPTAKE; DRUG URINE LEVEL; FIBROSARCOMA; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; C3H MOUSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG MONITORING; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; DIDEOXYNUCLEOSIDES; DRUG MONITORING; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; MICE; MICE, INBRED C3H; MICE, NUDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 0037742189     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J., and Laco, G. S. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Updat., 2: 307-318, 1999.
2. 1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem., 8: 1487-1503, 2001.
3. Matter, A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today, 6: 1005-1024, 2001.
4. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian. M. C., and Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. (Bethesda), 92: 205-216, 2000.
5. Padhani, A. R., and Husband, J. E. Are current tumor response criteria relevant for the 21st century? Br. J. Radiol., 73: 1031-1033, 2000.
6. 11C labeled thymidine for tumor visualization using positron emission tomography. Int. J. Appl. Radiat. Isot., 35: 705-708, 1984.
7. Martiat, P., Ferrant, A., Labar, D., Cogneau, M., Bol, A., Michel, C., Michaux, J. L., and Sokal, G. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J. Nucl. Med., 29: 1633-1637, 1988.
8. Eary, J. F., Mankoff, D. A., Spence, A. M., Berger, M. S., Olshen, A., Link, J. M., O'Sullivan, F., and Krohn, K. A. 2-[C-11]Thymidine imaging of malignant brain tumors. Cancer Res., 59: 615-621, 1999.
9. Shields, A. F., Mankoff, D. A., Link, J. M., Graham, M. M., Eary, J. F., Kozawa, S. M., Zheng, M., Lewellen, B., Lewellen, T. K., Grierson, J. R., and Krohn, K. A. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med., 39: 1757-1762, 1998.
10. Eary, J. F., Mankoff, D. A., Thompson, J. A., Gold, P., and Krohn, K. A. Tumor metabolism and proliferation using quantitative PET imaging in renal cell carcinoma patients treated with IL-2. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13 (Suppl.): 338a, 1999.
11. Wells, P., Gunn, R. N., Alison, M., Steel, C., Golding, M., Ranicar, A. S., Brady, F., Osman, S., Jones, T., and Price, P. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res., 62: 5698-5702, 2002.
12. 18F]FLT and positron emission tomography. Nat. Med., 4: 1334-1336, 1998.
13. Schields, A. F., Ho, P. T., and Grierson, J. R. The role of imaging in the development of oncological agents. J. Clin. Pharmacol., 39: 40-44, 1999.
14. Langen, P., Etzold, G., Hintsche, R., and Kowollik, G. 3′-Deoxy-3′-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol. Med. Ger., 23: 759-766, 1969.
15. Flexner, C., van der Horst, C., Jacobson, M. A., Powderly, W., Duncanson, F., Ganes, D., Barditch-Crovo, P. A., Petty, B. G., Baron, P. A., and Armstrong, D. Relationship between plasma concentration of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J. Infect. Dis., 170: 1394-1403, 1994.
16. Sundseth, R., Joyner, S. S., Moore, J. T., Dornsife, R. E., and Dev. I. K. The anti-human immunodeficiency virus agent 3′-fluorothymidine induced DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob. Agents Chemother., 40: 331-335, 1996.
17. Kong, X. B., Zhu, Q. Y., Vidal, P. M., Watanabe, K. A., Polsky, B., Armstrong, D., Ostrander, M., Lang, S. A., Jr., Muchmore, E., and Chou, T. C. Comparison of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother., 36: 808-818, 1992.
18. Rasey, J. S., Grierson, J. R., Wiens, L. W., Kolb, P. D., and Schwartz, J. L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med., 43: 1210-1217, 2002.
19. Ellims, P. H., Van der Weyden, M. B., and Medley, G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res., 41: 691-695, 1981.
20. Munch-Petersen, B., Cloos, L., Jensen, H. K., and Tyrsted, G. Human thymidine kinase. 1. Regulation in normal and malignant cells. Adv. Enzyme Regul., 35: 69-89, 1995.
21. Sherley, J. L., and Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 263: 8350-8358, 1988.
22. 18F-labelling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. J. Fluorine Chem., 55: 283-289, 1991.
23. Grierson, J. R., Shields, A. F., and Eary, J. F. Development of a radiosynthesis for 3′-[F-18]fluoro-3′-deoxynucleosides. J. Labelled Compounds Radiopharm., 40: 60-62, 1997.
24. 18F]FLT; portrait of a proliferation marker. Eur. J. Nucl. Med. Mol. Imag., 29: 165-169, 2001.
25. Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Liewald, F., Reske, S. N., and Neumaier, B. 3-Deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res., 62: 3331-3334, 2002.
26. 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res., 58: 1063-1067, 1998.
27. Moore, M. J., and Erlichmann, C. Pharmacology of anticancer drugs. In: I. F. Tannock and R. P. Hill (eds.), The Basic Science of Oncology, pp. 370-391. New York: McGraw-Hill, 1998.
28. 18F]FLT) and the fate of the precursor 2,3′-anhydro-5′-O-(4,4′-dimethoxytrityl)-thymidine. J. Labelled Compounds Radiopharm., 44 (Suppl. 1): 871-873, 2001.
29. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med., 27: 235-238. 1986.
30. He, Q., Skog, S., Wang, N., Eriksson, S., and Tnbukait, B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker of cell proliferation. Eur. J. Cell Biol., 70: 117-124, 1996.
31. He, Q., Zou, L., Zhang, P. A., Lui, J. X., Skog, S., and Fornander, T. The clinical significance of thymidine kinase I measurement in serum of breast cancer patients using anti-TK1 antibody. Int. J. Biol. Markers, 15: 139-146, 2000.
32. Jeavons, A. P., Chandler, R. A., and Dettmat, C. A. A 3D HIDAC-PET camera with sub-millimetre resolution for imaging small animals. IEEE Trans. Nucl. Sci., 46: 468-473, 1999.
33. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur. J. Cancer, 35: 1773-1782, 1999.
34. Hatanaka, M., Augl, C., and Gilden, R. V. Evidence for a functional change in the plasma membrane of murine sarcoma virus-infected mouse embryo cells. Transport and transport-associated phosphorylation of 14C-2-deoxy-D-glucose. J. Biol. Chem., 245: 714-717, 1970.
35. Gallagher, B. M., Fowler, J. S., Gutterson, N. I., MacGregor, R. R., Wan, C. N., and Wolf, A. P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J. Nucl. Med., 19: 1154-1161, 1978.
36. Kubota, R., Yamada, S., Kubota, K., Ishiwata, K., Tamahashi, N., and Ido, T. Intratumoral distribution of 18F-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med., 33: 1972-1980, 1992.
37. Kubota, R., Kubota, K., Yamada, S., Tada, M., Ido, T., and Tamahashi, N. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J. Nucl. Med., 35: 1067-1075, 1994.
38. Reinhardt, M. J., Kubota, K., Yamada, S., Iwata, R., and Yagashi, H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J. Nucl. Med., 38: 280-287, 1997.
39. 18F-FLT in patients. J. Nucl. Med., 41 (5 Suppl.): 36p, 2000.
40. Conti, P. S., Hilton, J., Wong, D. F., Alauddin, M. M., Dannals, R. F., Ravert, H. T., Wilson, A. A., and Anderson, J. H. High performance liquid chromatography on carbon-11 labeled thymidine and its major catabolites for clinical PET studies. Nucl. Med. Biol., 21: 1045-1051, 1994.
41. Court, M. H. Acetaminophen UPD-glucuronosyltransferase in ferrets: species and gender differences, and sequence analysis of ferret UGT1A6. J Vet Pharmacol. Ther., 24: 415-422, 2001.
42. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl. Med. Biol., 29: 281-287. 2002.
43. 18F]FLT) in pancreatic cancer cell lines. Eur. J. Nucl. Med. Mol. Imag., 29: 1174-1181, 2002.
44. 18F]FLT for breast cancer imaging. J. Nucl. Med., 42 (Suppl.): 29, 2001.
45. Li, S. J., Wehrle, J. P., Glickson, J. D., Kumar, N., and Braunschweiger, P. G. Tumor bioenergetics and blood flow in RIF-1 murine tumors treated with 5-fluorouracil. Magn. Reson. Med., 22: 47-56, 1991.
46. Sherley, J. L., and Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 262: 8350-8358, 1988.
47. Sutterluety, H., Bartl, S., Dötzlhofer, A., Khier, H., Wintersberger, E., and Seiser, C. Growth-regulated antisense transcription of the mouse thymidine kinase gene. Nucleic Acids Res., 26: 4989-4995, 1998.
48. Tommasi, S., and Pfeifer, G. P. Constitutive protection of E2F recognition sequences in the human thymidine kinase promotor during cell cycle progression. J. Biol. Chem., 272: 30483-30490, 1997.
49. Sorensen, P., and Wintersberger, E. Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promotor. J. Biol. Chem., 274: 30943-30949 1999.
50. Celis, J. E., and Celis, A. Cell cycle-dependent variations of the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc. Natl. Acad. Sci. USA, 82: 3262-3266, 1985.
51. Mathews, M. B., Bernstein, R. M., Franza, B. R., Jr., and Garrels, J. I. Identity of the proliferating cell nuclear antigen and cyclin. Nature (Lond.), 309: 374-376, 1984.